Search IconSearch
April 29, 2024/Cancer

Scrambler Technology Life Changing for Many Patients with Neuropathic Pain

Novel therapy “retrains” the brain to disrupt pain signals

Scrambler therapy for nerve pain

Peripheral neuropathy is a common side effect of chemotherapy and radiation, leaving patients with pain, a stabbing or burning sensation and/or numbness in their hands and feet. Pain medications often don’t provide total relief. Scrambler Therapy® is a novel approach to break the cycle of pain without using medications.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Chemotherapy and radiation therapy can cause nerve cells in the body to become damaged, resulting in wrong signals being sent to pain centers in the brain. This causes neuropathic pain. Scrambler Technology is an FDA-approved device that uses electro-analgesia therapy for the noninvasive treatment of chronic neuropathic symptoms, such as pain, tingling, numbness and cold/warm sensation.

"For patients experiencing chronic pain, there is a painful stimulus that is a constant occurrence that gets disassociated from the actual cause of the pain,” explains Chirag Patel, MD, a palliative medicine specialist with Cleveland Clinic Cancer Institute. “The nerve fibers that are transmitting pain signals get in the habit of doing so. Usually there’s some damage that’s caused the pain and over time, the nerve fibers essentially get hardwired to transmit pain signals. So even when the damage is not an actively occurring process anymore, pain signals are still being sent to the brain.”

The Scrambler device disrupts this pain cycle. Using electrodes similar to the ones used for EKG that are carefully placed near the area(s) of pain, the device produces small electrical currents. The currents activate C fibers, producing non-pain signals that override native pain-generating signals. Over the course of multiple treatments, the brain becomes accustomed to experiencing the non-pain signals instead of the pain signals.

“The therapy essentially retrains the brain to feel new signals created by the device instead of feeling pain signals,” explains Renato Samala, MD of Cleveland Clinic Cancer Institute’s Palliative and Supportive Care department. “This can really improve a patient’s quality of life."

People sometimes wonder if the device works the same way as a transcutaneous electrical nerve stimulation (TENS) machine, but the mechanism of action is different. TENS units use electric pulses to prevent pain signals from reaching the spinal cord and brain in the moment, but when the treatment ends, the pain returns. Scrambler Technology is designed to offer long-term alleviation of pain.


Though the therapy doesn’t work for everyone, for those that it does, the experience can be life changing. One cancer survivor with neuropathy caused by chemotherapy previously described his pain as feeling like stepping on sharp objects all the time. “We treated him for four sessions with Scrambler Therapy and the pain was totally gone,” says Dr. Samala. “He’s doing well and enjoying outdoor activities again.”

The therapy may be used for patients with longstanding neuropathic pain or other symptoms of chronic neuropathy involving the arms, legs or trunk. Cleveland Clinic Cancer Institute is currently offering the therapy to adult patients with chemotherapy-induced peripheral neuropathy or chronic neuropathy from other causes.

This therapy may be appropriate for patients for whom conventional treatments like gabapentin or pregabalin haven’t helped, or who are seeking an alternative to pain medications. Typically, patients receive the treatment in 30-60-minute sessions daily for two weeks. Many patients report feeling a sensation like vibrating or buzzing during the session but should not feel any discomfort. Patients first undergo an evaluation to see if they would benefit from Scrambler Therapy. “Pain should improve right after treatment for us to know that Scrambler Therapy is right for them,” says Dr. Samala. “If this happens, then the full 10-day treatment course will be offered.”

The treatment cannot be administered while patients are still undergoing chemotherapy with certain drugs or radiation therapy. However, those who have completed their course of chemotherapy or radiation therapy and are experiencing pain or numbness in their extremities may be a candidate.

Contraindications for the therapy include:

  • Operational implanted drug delivery system, implanted electronic medical device, life supporting medical device and/or medical monitoring device
  • History of epilepsy, brain damage or current use of anticonvulsants for seizures
  • History of myocardial infarction or ischemic heart disease within the past six months
  • Pregnancy or nursing
  • Skin conditions, such as wounds that will prevent proper application of electrodes


Related Articles

Dr. Grobmyer and team
June 14, 2024/Cancer/Innovations
Fatima bint Mubarak Center Addresses Inequities in Cancer Care

Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

car T-cells
June 3, 2024/Cancer/Research
CAR T-Cell Treatment Offers Hope for Richter Transformation

Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel

Blood clot
May 17, 2024/Cancer/Research
Managing the Risks of Venous Thromboembolisms in Patients with Cancer

Oral anticoagulants may be beneficial but need to be balanced against bleeding risks

Director of the Novel Cancer Therapeutics Center
May 2, 2024/Cancer/Innovations
Oncology Pharmacovigilance Clinic Expands Specialties

First-of-its-kind clinic for immune-related adverse events supports oncologists in managing severe side effects

Women's health physician
April 16, 2024/Cancer
Watching Out for Primary Ovarian Insufficiency

An underdiagnosed condition in patients with cancer